BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35762528)

  • 1. Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry.
    Li Y; Jiang L; Wang Z; Wang Y; Cao X; Meng L; Fan J; Xiong C; Nie Z
    Anal Chem; 2022 Jul; 94(27):9894-9902. PubMed ID: 35762528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted and untargeted urinary metabolic profiling of bladder cancer.
    Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Nieczaj A; Nizioł J
    J Pharm Biomed Anal; 2023 Sep; 233():115473. PubMed ID: 37229797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of carbonyl metabolic fingerprints in urine of Graves' disease patients based on atmospheric ionization mass spectrometry.
    Wang Y; Wan L; Li Y; Qu Y; Qu L; Ma X; Yu Y; Wang X; Nie Z
    Talanta; 2024 May; 277():126329. PubMed ID: 38815320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach.
    Huang Z; Lin L; Gao Y; Chen Y; Yan X; Xing J; Hang W
    Mol Cell Proteomics; 2011 Oct; 10(10):M111.007922. PubMed ID: 21799048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
    Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
    Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
    Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
    Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging.
    Vanarsa K; Castillo J; Wang L; Lee KH; Pedroza C; Lotan Y; Mohan C
    BMC Med; 2023 Apr; 21(1):133. PubMed ID: 37016361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer.
    El-Shal AS; Shalaby SM; Abouhashem SE; Elbary EHA; Azazy S; Rashad NM; Sarhan W
    Mol Biol Rep; 2021 May; 48(5):4361-4371. PubMed ID: 34085193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
    Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
    Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
    Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
    Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry.
    Issaq HJ; Nativ O; Waybright T; Luke B; Veenstra TD; Issaq EJ; Kravstov A; Mullerad M
    J Urol; 2008 Jun; 179(6):2422-6. PubMed ID: 18433783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria.
    Piao XM; Jeong P; Kim YH; Byun YJ; Xu Y; Kang HW; Ha YS; Kim WT; Lee JY; Woo SH; Kwon TG; Kim IY; Moon SK; Choi YH; Cha EJ; Yun SJ; Kim WJ
    Int J Cancer; 2019 Jan; 144(2):380-388. PubMed ID: 30183088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
    Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
    PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
    Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
    Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.
    Ng K; Stenzl A; Sharma A; Vasdev N
    Urol Oncol; 2021 Jan; 39(1):41-51. PubMed ID: 32919875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
    Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
    J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.